OCSOculis Holding AG

Healthcare
$8.62-55% 1Y

Price

-55%1Y

End-of-day closes, not the intraday tick.

RyuScore

Weak, higher than 3% of companies
7/100
Seven criteria, weighted: see how it is built

The five questions

2 of 5 available

Only two of the five can be answered for OCS today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.

  • Is the business good?not enough filed
  • Is it safe?Watch
  • Is the price fair?not enough filed
  • Is it growing?not enough filed
  • What is the market doing?Watch
P/En/a
Market value$520.5M
1 year-55%
5 years-11%

Charts

As reported to the SEC, without any scoring.

Oculis Holding AG (OCS) reported revenue of CHF 654K in H2 2025 (quarter ended Dec 31, 2025), up 167% from the same quarter a year earlier. That came with net loss of CHF 40M. For the full year FY2025, revenue was CHF 1.2M (+75% year on year) and net income −CHF 99M.

Biotechnology

Ranks #165 of 196 by RyuScore

Compare peers
ACRS+12%
Aclaris Therapeutics, Inc.
DRUG+0.58%
BRIGHT MINDS BIOSCIENCES INC.
PBYI+1.6%
PUMA BIOTECHNOLOGY, INC.
NVCT-0.98%
Nuvectis Pharma, Inc.
CTMX-3.1%
CytomX Therapeutics, Inc.
HELP+2.2%
CYBIN INC.